Biocon Biologics, Viatris receive EC approval for biosimilar insulin as part Kixelle

Biocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-developed with NASDAQ-listed Viatris Inc., has received marketing authorisation approval from the European Commission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3rF8az0
via IFTTT